Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
Stripe, Advent Offer Over $53 Billion to Acquire PayPal in Major Fintech Deal 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
Stripe, Advent Offer $53 Billion Deal to Acquire PayPal: Reuters 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
NEW YORK, Jan. 20, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of MannKind Corporation (“MannKind” or the “Company”) (Nasdaq:MNKD) between August 10, 2015 and January 5, 2016.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired MannKind securities between August 10, 2015 and January 5, 2016, your rights may be affected by this action. To get more information go to:
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants’ assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company’s rapid-acting insulin; and (2) as a result, Defendants’ statements about MannKind’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
